Mitofusin-2 knockdown increases ER-mitochondria contact and decreases amyloid β-peptide production

Nuno Santos Leal1, Bernadette Schreiner1, Catarina Moreira Pinho1

  • 1Center for Alzheimer Research, Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.

Insights

Altering contact between the endoplasmic reticulum (ER) and mitochondria impacts Alzheimer's disease (AD) pathology. Increased ER-mitochondria contact reduces amyloid-beta (Aβ) generation by impairing γ-secretase activity.

Area of Science:

  • Cell Biology
  • Neuroscience
  • Biochemistry

Background:

  • Mitochondria and endoplasmic reticulum (ER) interact at mitochondria-associated ER membranes (MAM).
  • Previous studies indicated increased MAM proteins and ER-mitochondria calcium (Ca2+) transfer in Alzheimer's disease (AD) models.
  • Amyloid-beta (Aβ) peptide is implicated in AD pathogenesis.

Purpose of the Study:

  • To investigate the role of mitofusin-2 (Mfn2) in ER-mitochondria contact and its effect on Aβ production.
  • To determine if modulating ER-mitochondria contact influences γ-secretase activity.

Main Methods:

  • Utilized siRNA to knockdown Mfn2, a protein mediating ER-mitochondria tethering.
  • Quantified ER-mitochondria contact and Ca2+ transfer.
  • Measured intra- and extracellular Aβ40 and Aβ42 concentrations.
  • Analyzed γ-secretase complex components, maturation, and activity.

Main Results:

  • Mfn2 knockdown increased ER-mitochondria contact and Ca2+ transfer.
  • Reduced intra- and extracellular Aβ40 and Aβ42 levels were observed with Mfn2 depletion.
  • Impaired γ-secretase complex function, not altered expression of APP or other proteases, accounted for decreased Aβ.
  • Increased ER-mitochondria contact led to decreased γ-secretase activity.

Conclusions:

  • Modulating ER-mitochondria contact influences γ-secretase activity and Aβ generation.
  • Enhanced ER-mitochondria physical interaction presents a novel mechanism for controlling Aβ production in AD.
  • Targeting Mfn2 or ER-mitochondria contact could be a therapeutic strategy for AD.